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Aprotein immunologically similar to themajorbasic protein ofeosinophil granules
(gMBP)' is present in high concentration in the plasma of pregnant women (1) . The
blood level ofthis pregnancy-associated major basic protein (pMBP) increases early
in gestation and plateaus by week 20 at concentrations more than 10 times normal .
Afteranotherincrease just before parturition, the peak level ofpMBP in pregnancy
approaches the levels seen in patients with the hypereosinophilic syndrome . pMBP
returns to baseline within 6 wk post partum . Unlike hypereosinophilic syndrome
plasma, however, pregnancy plasma does not contain increased amounts of other
eosinophil granule-derived proteins such as eosinophil-derived neurotoxin, eosino-
phil cationic protein, or Charcot-Leyden crystal (1) . In addition, there is no eosinophilia
demonstrable in peripheral blood, uterus, or placenta during pregnancy (1, 2) . These
observations and the immunofluorescent localization ofpMBP in fetally derivedX
cells and giant cells in human placentae (2) suggest that pMBP is not derived from
the eosinophil .
Despite theirapparent origin from different cells, pMBP andgMBP are identical
in their reactivities with polyclonal rabbit antisera (1) andapanel of 14 mouse mAbs
(3). The following study was undertaken to define the chemical basis for this im-
mune crossreactivity . Theresults indicate that thepMBP is virtually identical chem-
ically to gMBP
Materials and Methods
Materials.
￿
gMBP wasprepared from human eosinophils as described (4, 5). Plasma samples
were obtained from pregnant women (third trimester), from patients with eosinophilia, and
from normal personsby centrifugation ofvenous blood(EDTAas an anticoagulant) andstored
at -20°C . Mouse mAbs against gMBP were prepared as described (6) by usingthe FOmy-
eloma fusion partner and purified from ascitic fluid by proteinA affinity chromatography.
PBS consisted of 0.003 M KCI, 0.001 MKH2PO4, 0.008 M Na 2HPO4, and 0.15MNaCl
This work was supported in part by research grants HD-22924, AI-09728, andAI-15231 from the Na-
tional Institutes of Health and by the Mayo Foundation . Address correspondence to Gerald J . Gleich,
M.D., Mayo Clinic, 200 First Street SW, Rochester, MN 55905. C. B . Coulam's current address is Meth-
odist Center for Reproduction and Transplantation Immunology, Methodist Hospital ofIndiana, Indi-
anapolis, IN 46202.
' Abbreviations used in this paper: gMBP, major basic protein of eosinophil granules ; NEpHGE, non-
equilibrium pH electrophoresis; pMBP, pregnancy gradient-associated major basic protein.
J . Exp. MED . ® The Rockefeller University Press " 0022-1007/89/12/2051/13 $2.00
Volume 170 December 1989 2051-2063
20512052
￿
EOSINOPHIL GRANULE MAJOR BASIC PROTEIN IN PLACENTA
at pH 7.4. PPFE buffer consisted of 0.1 M P04 (pH 7.4), 0.5% FCS, 0.1% NaN3, 0.01 M
EDTA, and 1% protamine sulfate (salmon, grade X) at pH 7.4. Placental cyst fluid was aspi-
rated from septal and subchorial cysts with a 3-ml syringe and stored at -20°C. Molecular
weight markers included transferrin, BSA, ovalbumin, trypsinogen, /3-lactoglobulin, cyto-
chrome c, blue dextran, and dinitrophenyllysine.
Reduction and Alkylation of Placenta-derived Fluids.
￿
5 vol of placental extract, cyst fluid, or
plasma was diluted in 13 vol of Tris buffer (0.33 M Tris, 0.15 M NaCl, and 0.01 M EDTA
at pH 8.1); 2 vol of 0.075 M dithiothreitol (in Tris buffer) was added and the solution was
incubated for 1 h at 22 °C. Then, 2 vol of 0.15 M iodoacetamide was added and the solution
was incubated for 20 min at 22°C. Samples were analyzed immediately or dialyzed against PBS.
Radioimmunoassayfor MBP.
￿
A competitive binding RIA with mAb was used to measure
MBP activity of both gMBP and pMBP. Briefly, FAST sticks (Falcon Labware, Becton Dick-
inson & Co., Lincoln Park, NJ) were coated with protein A-purified J14-7A2 anti-gMBP
mAb (10 Wg/ml in PBS) and blocked with PPFE buffer. Reduced and alkylated unknowns
or gMBP standards were diluted in PPFE buffer; 100-ul portions were placed in 96-well plates
with 100 P.1 of 1211-labeled gMBP (5 ng/ml, 30 P,Ci/Pg) and incubated with mAb-coated sticks
for 18 h at 4°C. The sticks were washed with PBS containing 0.05% Tween 20 and assayed
in a gamma counter. MBP activity was quantitated from a gMBP standard curve with a
Hewlett-Packard computer (HP 9845; program 15031). Radioiodination of gMBP (and other
proteins) was performed by the chloramine T method (7).
Purification ofpMBP.
￿
pMBP was purified from placental septal fluids and extracts of septa
by a four-step procedure. First, placental septa were diced into 5-mm pieces and suspended
in extraction buffer (0.15 M NaCl, 0.01 M EDTA, 0.5 mM PMSF, and 0.33 M Tris at pH
8.1) using 2 vol of buffer per gram of tissue. The suspension was homogenized in a Waring
blender (3 min, 4°C), digested with collagenase (0.1% collagenase, type IV, in 0.02 M CaC12
for 5 h at 37 °C) and with deoxyribonuclease (400 U of DNase per milliliter of extract in
0.004 M MgC12 for 5 h at 37°C), and centrifuged at 10,000 g for 10 min. The extract was
stored at -20°C . Total protein was measured by the Lowry (8) or biuret assay (9).
Second, pMBP was purified by affinity chromatography. Protein A-purified mAb anti-
gMBP (J14-7A2, orJ6-8A4) was immobilized on cyanogen bromide-activated Sepharose 413
(Sigma Chemical Co., St. Louis, MO) according to the manufacturer's instructions (5-10
mg of mAb per milliliter of gel). Reduced and alkylated placental septal extracts or cyst fluid
were applied to the mAb columns (1 x 10 cm), washed extensively with PBS (6 ml/h, upward
flow) until the absorbance at 280 nm was <0.02, washed with 0.5 M NaCl, 0.3 M Tris at
pH 8.0 (3 column volumes), and eluted with 0.1 M glycine-HC1 at pH 3 .0.
Third, gel filtration chromatography in the presence of a dissociating solvent was used
to fractionate pMBP by molecular size. Eluates from the affinity purification were equilibrated
with 6 M guanidine-HCl (GuCI), reduced and alkylated again, and fractionated on Sepharose
CL-613 equilibrated with 6 M GuCl. The molecular weight of pMBP was calculated as de-
scribed by Mann and Fish (10). pMBP-containing fractions were detected by dot blot assay
or measured by RIA after dialysis against PBS. pMBP-containing pools were desalted over
Sephadex G-15 (1 x 15 cm column, 0.5 M acetate buffer, 5 ml/h).
Fourth, pMBP was purified by reversed-phase HPLC on a microBondpak C,e column (25
cm x 10 pro) (Waters Associates, Milford, MA). The starting buffer was 0.1% trifluoroacetic
acid, and proteins were eluted by a linear gradient (0-100%) of 90% CH3CN in 0.1%
trifluoroacetic acid. Protein-containing fractions were detected by absorbance at 280 nm,
pooled, and lyophilized.
Gel Electrophoresis and Western Blot Assay.
￿
One-dimensional SDS-PAGE and two-dimensional
nonequilibrium pH gradient electrophoresis (NEpHGE)/SDS-PAGE were performed as de-
scribed (11). Proteins were detected by silver staining (12). The Western blot assay (immuno-
assay) was performed by electrophoresic transfer of proteins to nitrocellulose (Transblot Cell;
Bio-Rad Laboratories, Rockville Center, NY) with 15 mM Tris, 192 mM glycine, and 20%
methanol at pH 8.3 and 90 V and 0.26 A for 1 h. Filters were blocked with 3% BSA in PBS
at pH 7.4 (1 h at 22 °C). MBP antigenic activity was detected by reaction of the filter with
a mixture of four mAbs (J14-7A2, J13-6136, J14-1C3, andJ6-8A4), each at 1 Fog/ml in PPF-E
buffer, for 2 h at 22 °C. After it was washed, the filter was exposed to sheep anti-mouse '25I-WASMOEN ET AL.
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labeled IgG, 20 ng/ml in PPFE buffer, for 18 h at 4"C. Paired filters were incubated with
normal mouse serum in the first stage as a negative control. The filters were extensively washed
with PBS containing 0.05% Tween 20 and autoradiographed at -70'C on XAR5 film
(Eastman Kodak, Rochester, NY). Dot blot assays were performed in the same manner ex-
cept that 25 pl of each column fraction was spotted directly onto the nitrocellulose.
Aptide Mapping
￿
For trypsin and cyanogen bromide digestions, '21I-labeled gMBP and
"'I-labeled pMBP were mixed, boiled in SDS sample buffer, and acetone precipitated in
the presence of 200 hg of BSA as a carrier. Trypsin digestion was performed in 200 Al of
0.1 M NH4HCOs at pH 7 .8; a total of 60 gg ofN-tosyl-L-phenylalanyl chloromethyl ketone
(TPCK) trypsin (Worthington Biochemical Corp., Freehold, NJ) added in three equal por-
tions over 9 h of incubation at 37'C was used. Cyanogen bromide digestion at tryptophan
residues was performed according to Huang et al. (13). In each case, the radiolabeled pep-
tides were separated by reversed-phase HPLC as described above and detected by analysis
of 1-ml fractions in a dual-channel gamma counter (TM 1191; TM Analytics, Elk Grove Vil-
lage, IL). The results were analyzed with a Hewlett-Packard computer (HP 9845)and a statis-
tical graphics program (No. 15021). gMBP or pMBP (10 Fog in 0.25% acetic acid) was cleaved
at aspartic acid residues by treatment at 105'C for 6 h in sealed glassvials. Cleavage products
were analyzed by SDS-PAGE.
Amino Acid Analysis.
￿
NH2-terminal analysis of pMBP and sequence determination of the
COOH-terminal peptide generated by cleavage in dilute acid were performed as described (11).
Results
Purification ofpMBP
Initial gel filtration of placental extracts indicated a mass of >1,000 kD (elution
in the void volume of Sepharose CL-4B columns) for pMBP (data not shown). Be-
cause this excessive size may have reflected polymerization or binding to a large car
rier molecule, subsequent studies used DNase treatment to minimize complexes with
DNA. However, even after nucleic acid removal, pMBP still eluted from Sepharose
CL-4B columns in multiple high molecular weight peaks, a behavior similar to that
ofplasma gMBP which binds to plasma proteins through ionic and disulfide bonds
(4); gMBP can be resolved to the monomer, -14 kD, by reduction and alkylation
and then acidification of plasma (4). Analogous interactions for pMBP are suggested
by its requirement for reduction and alkylation in order to maximize immunoreac-
tivity with polyclonal antisera (1) and mAbs (3) and by its low molecular weight,
as judged by immunodiffusion after reduction under denaturing conditions (results
not shown) and by Western blot analysis (see below).
AfterDNase digestion and reduction and alkylationofplacental extracts, to mini-
mize pMBP interactions with DNA and placental proteins, respectively, pMBP was
partially purified from placental extracts or cyst fluid by affinity chromatography
with mAb immobilized on Sepharose 4B. The resulting preparations were 300-700-
fold enriched from placental extracts and 50-150-fold enriched from cyst fluid with
70% to almost 80% recoveries (Table 1). Eluates were analyzed by SDS-PAGE and
Western blot assay to detect immunoreactive MBP Multiple proteins were present
in these eluates even though the immunoprecipitates had been washed with buffers
containing high salt concentration (Fig. 1 A). Two immunoreactive species with mo-
lecular masses of ti14 and 30 kD were present in affinity-purified cyst fluid and
placental extract (Fig. 1 B). The 30-kD molecule was replaced by a 14-kD molecule
when the eluates were reduced in 8 M urea and therefore it appears to be a SDS-
stable polymer (data not shown). Purified eosinophil gMBP polymerizes on storage
to yield a 30-kD SDS-stable species (Fig. 1 B).2054
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TABLE I
Purification ofpMBP From Placental Extracts and Cyst Fluid
Measured by RIA .
t Measured by biuret method .
4 Measured by Lowry method .
On gel filtration of affinity-purified pMBP over Sephadex G-200 equilibrated with
0.01 M HCl and 0.15 M NaCl (a procedure that releases monomer gMBP from
plasma protein complexes [1]), pMBP eluted in the void volume (>400 kD) (data
not shown) . This result is in contrast to the size of 14 kD shown on Western blots
(Fig . 1 B) and suggests that the complexes of pMBP with placental proteins can
be disrupted only by more stringent denaturing solvents . Therefore, the second
purification step used gel filtration over Sepharose CL-6B in the presence of 6M
GuCl (Fig . 2) . Column fractions were screened for pMBP by dot blot assay, and
FIGURE 1 .
￿
SDS-PAGE (A)and
Western blot assay (B) ofgMBP
and affinity-purified pMBP.
pMBP was purified from re-
duced and alkylated placental
extracts or cyst fluid by affini-
ty chromatography. Molecular
mass markers (kilodaltons) are
indicated to the left . (A) SDS-
PAGE (under reducing condi-
tions) . Lanes : (1) purified eosin-
ophilgMBP ; (2)column eluate
of cyst fluid ; (3) column eluate
ofplacental extract. gMBP (lane
1) migrated with mass 14.5kD.
(B) Western blot assay . Proteins
separated by SDS-PAGE were
transferred electrophoretically
to nitrocellulose . Immunore-
active MBP was detected by
usingmAbanti-gMBP followed
by sheep anti-mouse 1211-la
beled IgG and autoradiography. A paired blot with normal mouse serum as the first-stage antibody
was negative (not shown). Lanes 1, 2, and 3 correspond to lanes 1, 2, and 3 inA ; (lane 4) eosinophil
gMBP stored for 6 mo at -70°C in nonreduced state (note stable 30-kD polymer) .
Purification step Volume
ml
Total
protein MBP`
jug
MBP (Wg/mg
protein) Recovery
From placental extract
Placental extract 150 7.4 91 629 0.066
Affinity chromatography 1 10 .1 mg : 492 48.7 78
Gel filtration in 6 M GuCl 1 2.6 mgs 450 173 72
Reversed-phase HPLC 1 300 ug § 250 833 39
From cyst fluid
Cyst fluid 19 1 .5 gl 391 0.26
Affinity chromatography 1 8.4 mgt 300 36 77
Gel filtration in 6 M GuCl 1 3 .8 mg5 300 79 77
Reversed-phase HPLC 1 250 14g5 200 800 51E
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FIGURE 2 . Sepharose CL-6B chromatog-
raphyin thepresence of6MGuCl ofaffinity-
purified pMBP from aplacental extract. Im-
munoreactive MBP was measured by RIA.
Molecularmass markers: blue dextran (Vo),
transferrin (T), BSA (B), ovalbumin (O),
0-lactoglobulin (L), cytochrome c(C), anddi-
nitrophenyllysine (Vi). pMBP mass = 14.7 kD.
positive fractions were dialyzed into PBS forMBP quantitation byRIA. Thecalcu-
lated mass for pMBPwas 14.7 kD, in keeping with the results on Western blot assay
(Fig. 1). In some cases, both the 14.7-kD molecule and the 30-kD polymer were de-
tected in column fractions. pMBP eluted from this column with a mass of13.8 kD
(data not shown).
pMBP-containing fractions from SepharoseCL-6B columns were desalted, lyophi-
lized, and subjected to reversed-phase HPLC (Fig. 3 A). Each protein peak wascol-
lected and subjected to SDS-PAGE followed by Western blot assay to detect MBP
Peak 5 gave a single band by SDS-PAGE (-15 kD) and a single spot by two-
dimensional gel electrophoresis (see below). Similar results were seen with purified
pMBP from cyst fluid. Fig. 4shows thepurity ofpMBPateach step ofthepurification.
Physicochemical Comparison ofpMBP andgMBP
Molecular Weight.
￿
Eosinophil gMBP has a predicted molecular weight of 14,047
based on its amino acid sequence (14), close to the values of 14,500 by SDS-PAGE
(Fig. 1) and 13,800 by elution from Sepharose CL-6B in the presence of6 MGuCl
(results not shown). The molecular weight ofpMBP estimated by these procedures
is also -14,000 (Fig. 1, 2, and 3). Further, the size similarity between gMBP and
pMBP is shown by their comigration in two-dimensional gels (see below).
Isoelectric Point.
￿
Eosinophil gMBP has an isoelectric point of 11.6 predicted by
its amino acid sequence (14). Theabsenceofampholytes capable ofcreating a stable
gradient in this pH range precludes the exact measurement ofthe PI ofgMBP and
pMBP However, NEpHGE, the firstdimension oftwo-dimensional gels, allows com-
parisonoftherelative migrations ofgMBP and pMBP inapH gradient. BothpMBP
and gMBP migrated >2 cm ahead of cytochrome c (pI = 10.6) when NEpHGE
focusing was performed for 2 h (500 V), indicating a pI for each of>10.6 (data not
shown). Because gradient formation may vary in side-by-side gels, mixing experi-
mentswere performed tocompare the relative migrations ofgMBP and pMBP When
trace amounts of "'I-labeled pMBP were added to 5 hg ofpurified gMBP, the mix-
ture wassubjectedto two-dimensional gel electrophoresis, andthe gelwas silver stained
todetect gMBP and autoradiographed todetect "'I-labeled pMBP, the pMBP spot
superimposed over the gMBP spot (Fig. 5, A and B). Comigration also was found
in the converse experiment with 5 lAg of purified pMBP and trace amounts of
121J_
labeled gMBP (Fig. 5, C and D).2056
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FIGURE 3 .
￿
Reversed-phase HPLC ofpMBP
(A) Partially purified pMBP from placental
extracts was applied to a reversed-phase
￿
C18
column and eluted with a linear gradient of
90% CH3CN in 0.1% trifluoroacetic acid
(buffer B) . Each peak was collected and ana-
lyzed by SDS-PAGE andWestern blot assay.
pMBP was found in peak 5, at 54% buffer
B . (B) SDS-PAGE. Protein peaks fromAwere
separated under reducingconditions and silver
stained. Lanes: (1) purified eosinophil gMBP ;
(2-7) peaks 2-7 from column in A . Size
markers (kilodaltons) are indicated at left .
gMBP (lane 1) migrated at 14.5 kD. (C)
Western blot assay . A duplicate of the SDS-
PAGE in B was transferred to nitrocellulose
andMBP was detected as described in Fig .
2 B . Lanes: (1) eosinophil gMBP ; (2-7) peaks
2-7 from column inA . pMBP was in peak
5 . Comparison of B and C indicates that
pMBP migrated at -15 kD.
Hydrophobicity.
￿
The interaction of purified gMBP andpMBP with a Cts reversed-
phaseHPLC column wasused tocompare the relative hydrophobicities ofthesetwo
proteins . When differentially radiolabeled forms ofthe proteins were analyzed simul-
taneously, 1251-labeled gMBP and 13'I-labeled pMBP coeluted on reversed-phase
HPLC (Fig. 6) .
Peptide Mapping .
￿
When "'I-labeled gMBP and "'I-labeled pMBP were mixed
and digested with trypsin, and the peptides generated were analyzed by reversed-
phase HPLC, the major peptide peaks for gMBP andpMBP coincided (Fig. 7 A) .
An identical result was obtained when the proteins were treated with cyanogen bro-
mide under conditions that cleave at tryptophan (Fig . 7 B) .
The third peptide mapping protocol used dilute acid to cleave gMBP at its lone
aspartic acid residue at position 71 to form two peptides that can be separated byWASMOEN ET AL .
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FIGURE 4 .
￿
SDS-PAGE ofpMBP at each purification step. Lanes : (1)
eluate from anti-MBP affinity column of placental extract ; (2) pMBP
pool from SepharoseCL-6Bcolumn run in 6M GuCl ; (3) purifiedpMBP
after reversed-phase HPLC . Size markers (kilodaltons) are indicated at
left . pMBP (lane 3) had a calculated molecular mass of 14 .5 kD.
SDS-PAGE (but not by reversed-phase HPLC) (14) . Similar treatment of pMBP
produced three bands on SDS-PAGE that represented nativepMBPandtwo cleavage
products that were identical in size to the peptides generated from gMBP (Fig. 8) .
Amino Acid Sequence.
￿
N112-terminal sequence analysis was attempted on three
samples ofpMBP without success. Appropriate cleavage of a radiolabeled control
protein indicated that this was not due to problems with the sequencer and sug-
FIGURE 5 .
￿
Comigration ofgMBP andpMBP on two-dimensional gel electrophoresis . Mixtures
of radiolabeled and unlabeled gMBP and pMBP were subjected to NEpHGE focusing in the
first dimension followed by size separation by SDS-PAGE . (A andB) Mixture of 5 feg ofgMBP
and 5 ng of 1311-labeled pMBP (purified from placental extracts), with spots detected by silver
staining (A) for gMBP and autoradiography (B) for 1311-labeled pMBP Note identity of posi-
tions. (C andD) Mixture of 5 jig ofpMBP purified from cyst fluid and 5 ng of 1251-labeled gMBP
with spots detected by silver staining (C) for pMBP and autoradiography (D) for 1251-labeled
gMBP, note identity of positions. (E and F) Same as C and D, except that pMBP was purified
from cyst fluid.2058
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FIGURE 6 .
￿
Coelution of gMBP and
pMBP on reversed-phase HPLC. A
mixture of 1211-labeledgMBP (O)and
"'I-labeled pMBP (") was subjected
to reversed-phase HPLC on a C,s
column with elution by a linear gra-
dient of 0-100% of 90% CH3CN in
0.1% trifluoroacetic acid . 1211 and "'I
in the 1-ml fractions were measured in
a dual-channel gamma counter. pMBP
and gMBP coeluted at54% CH3CN.
gested chemical blockage of thepMBP NH2 terminus . The peptide mapping studies
outlined above suggested the possibility of determining thesequence oftheCOOH-
terminal peptide generated by cleavage at aspartic acid . When pMBP was digested
in dilute acid and the peptide mixture was analyzed directly, a single amino acid
sequence was obtained that corresponded exactly with the sequence ofresidues 72-92
of gMBP (Fig . 9) .
Discussion
Two sources ofpMBP were used forpurification . Fluid from placental subchorial
and septal cysts is therichestsource ofpMBP (up to 100 Wg/ml) (1)but is not suitable
as the sole source ofpMBP because of the rarity of cysts containing large amounts
FIGURE 7 .
￿
Peptide maps after diges-
tion of mixture of 1211-labeled gMBP
(O) and "'I-labeled pMBP (0) . (A)
Trypsin digestion . Radiolabeled pep-
tides were separated by reversed-phase
HPLC on a Cis column with a
0-70% gradient of 90% CH3CN in
0.1% trifluoroacetic acid . 1-ml fractions
were collectedandanalyzed in a dual-
gamma counter. (B) Cyanogen bro-
mide cleavage (at tryptophan). Radio-
labeled peptides were separated and
measured as in A .WASMOEN ET AL.
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FIGURE 8 .
￿
Cleavage ofgMBP andpMBP at aspartic acid . gMBP and
pMBP weredissolved separately in 0.25Macetic acid andincubated for
6h at 105°C .The peptidesgenerated wereseparated by SDS-PAGE . Lanes:
(1) undigested gMBP; (2) partial digestion ofpMBP showing nativepro-
tein (top band)and two digestion products (7 .2 and 4.8 kD) ; (3) partial
digestion ofgMBP, showing native protein (top band)andtwo digestion
products (8.25 and 4.80 kD). Size markers are indicated at left.
FIGURE 9 . Amino acid sequence of 000H-
70
￿
75
￿
OD
￿
85 ￿so
￿
terminal peptide of pMBP after cleavage at
gMBP
￿
V-D-Ci-SR-W-N-FA-Y-W-A-A-H-Q-PW-S-R-GG-H-C
￿
aspartic acid . The single amino acid sequence of
20 residues aligned perfectly with the sequence
pMBP
￿
-G-S-R-W-N-F-A-Y-W-A-A-H-Q-P-WSR-GG-H-
￿
of gMBP (residues 72-92) derived from dilute
acid cleavage .
of fluid . Therefore, initial purification efforts focused on extracts of placental septal
tissue.
Affinity chromatography was chosen as an early purification step because of its
specificity, high yield, andability to process large volumes. Attempts to purifypMBP
by affinity chromatography before removal ofDNA from placental extracts were
unsuccessful, probablydueto the inaccessibility ofepitopes asaresult ofDNA-pMBP
interaction . Such complexeswere demonstrated by phase partitioning and hydroxyl-
apatite adsorption that removedboth nucleic acids andpMBP (3). These complexes
could notbe disruptedby 2MNaCl, which removes lysine-richhistones fromDNA,
but they were separated by2M GuCl, which removes the more tightly bound arginine-
rich histones from DNA (15) . The results are consistent with the hypothesis that
pMBP is an arginine-rich basic protein and so is chemically related to gMBP (14) .
Disruption ofpMBP-DNA complexes with 2MGuCI decreased antibody binding,
presumably because it caused protein denaturation, and so extracts were treated
only with DNase before affinity chromatography.
Although affinity chromatography resulted in significant purification ofpMBP
from both placental extracts and cyst fluid, several observations indicated that the
isolated pMBPwas polymerized or bound to carrier proteins . Therefore, gel filtra-
tion in thepresence ofadenaturing solvent (6MGuCl) was used in order to disrupt
pMBP interactions with other molecules . This procedure was successful in separating
monomerpMBP (14kD) from the other proteins present, analogous to results with
eosinophil gMBP in the plasma of patients with hypereosinophilic syndrome, which
has been shown to polymerize and bind to plasma proteins by ionic and disulfide
bonds (4). However, those conditions (reduction, alkylation, and acidification) are
inadequate to separate the pMBP found in pregnancy plasma (1). The more rig-2060
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orous conditions necessary to disrupt pMBP-protein complexes may reflect chem-
ical differences between gMBP and pMBP or, more probably, a higher affinity of
bindingof pMBP to pregnancy-associated proteins, the bulk ofwhich arevery acidic
(16).
Another similarity between pMBP and gMBP is the ability to self-polymerize.
Several lines ofevidence suggest that the30-kD pMBP species seen in some extracts
and cyst fluid represents a polymer: (a) the 30-kD and 14-kD species coeluted on
reversed-phase HPLC, (b)the isolated 30-kD proteinwas replaced by a 14-kDmole-
cule when reducedin 8 Murea, and (c) peptide mappingstudiesperformedon prepa-
rationsofpMBP contaminated with the 30-kD molecule gave the same peptidemaps
as the pure 14-kD protein did (data not shown). On prolonged storage, gMBP also
formed a SDS-stable 30-kD polymer.
The final purification step, reversed-phase HPLC, relied on hydrophobicinterac-
tion to separate pMBP from other proteins and resulted in ahomogeneous product
as determined by one- and two-dimensional gel electrophoresis. Becausethe placenta
is such a vascular organ, the question can be raised whether the purification out-
lined above simply selects for contaminating gMBP from the plasma in this organ.
This possibility is excluded by the yield of pMBP per milliliter of extract and by
the recovery of >200 jug of pMBP from only 19 ml ofcyst fluid (Table I). Only nano-
gram quantities would be expected from similar volumesof plasma because eosino-
phil gMBP is present in the plasma of normal humans at 200-400 ng/ml (4). An-
otherpossibility is that the pMBP isolated from theplacenta is derived from eosinophils
in maternal or fetal blood. In the case of septa, this possibility is unlikely because
very few eosinophils are present in these tissues; in the case of the cyst fluid, this
possibility can be excluded because eosinophils are not present in the cyst fluid or
in the septal tissues surrounding the cysts (2).
During pMBP purification, many characteristics of this protein were found to
resemble those of gMBP In addition, gMBP and pMBP have the same molecular
mass (by both SDS-PAGE and gel filtration), isoelectric point (comigration in
NEpHGE), and relative hydrophobicity (coelution on reversed-phase HPLC). Se-
quence similarities are indicated by indistinguishable peptidemaps afterthree sepa-
rate digestions. Thus, these studies provide strong evidence that gMBP and pMBP
are identical except for the blocked NH2 terminus on pMBP Furthermore, the
cloning of eosinophil MBP from a human placental cDNA library supports these
findings (17).
The apparent identity of gMBP and pMBP raises important questions as to the
cell source of pMBP and its biologic function in the placenta. Eosinophil gMBP
is cytotoxic to mammalian cells (18, 19) and parasites (20). It also is known to affect
clotting (21), to induce histamine release from rat mast cells and human basophils
(22, 23), and to affect the response of tracheal muscle to contractile stimuli (24, 25).
Thechemical similarities between pMBP and gMBP suggestthat the placental pro-
tein may have similar biologic effects. pMBP may be produced by fetally derived
X cells (2). These cells are the most invasive form of trophoblasts (26), penetrating
deep into the decidua and myometrium. Thus, the question arises as to whether
a cytotoxin (like gMBP) couldfacilitate this invasion. In fact, earlyincreasesin plasma
level of pMBP during pregnancy do correlate with implantation (27). There is an-
other sharp increase in plasma pMBP concentration late in pregnancy that is as-sociated with the onset oflabor (27). The possibility that pMBP is involved in the
initiation of labor is suggested by the known effects of gMBP on tracheal smooth
muscle contractility (24, 25). The cynomolgus monkey, which also produces placental
pMBP (28), may be a model system for investigation ofthe role ofpMBP in primate
reproduction.
Summary
A protein immunochemically related to the eosinophil granule major basic pro-
tein (gMBP) is found in increased concentration in the plasma of pregnant women
and has been localized to placental trophoblasts by immunofluorescence. Pregnancy
MBP (pMBP) is indistinguishable from gMBP in its reactivity with polyclonal an-
tisera and a panel of 14 mouse mAbs. We report the purification of pMBP from
human placenta by: (a) affinity chromatography over mAb immobilized on Sepharose,
(b) gel filtration in 6 M guanidine-HCI buffer, and (c) reversed-phase HPLC. Purified
pMBP and gMBP are biochemically indistinguishable in that both: (a) bind to DNA,
(b) polymerize and bind to carrier proteins via disulfide linkages, (c) have a molec-
ular weight of 14,000, (d) have isoelectric points >10.6, (e) comigrate in two-
dimensional gels, 0 coelute during reversed-phase HPLC on C18 columns, (g) have
identical peptide maps after three different digestions, and (h) have partial amino
acid sequence identity. This physicochemical identity has important implications
as to the role of pMBP in human placentation.
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